Genetic Signatures Stock

Genetic Signatures Equity

The The Equity of Genetic Signatures (GSS.AX) as of Sep 12, 2026 is 50.09 M AUD. In the previous year, The Equity was 61.10 M AUD — a change of -18.02% (lower).

Equity

50.09 MAUD

YoY

-18.02%

Last updated:

In 2026, Genetic Signatures's equity was 50.09 M AUD, a -18.02% increase from the 61.10 M AUD equity in the previous year.

The Genetic Signatures Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2018
13.40 M AUD
Jan 1, 2019
10.57 M AUD
Jan 1, 2020
45.93 M AUD
Jan 1, 2021
49.34 M AUD
Jan 1, 2022
54.80 M AUD
Jan 1, 2023
42.91 M AUD
Jan 1, 2024
61.10 M AUD
Jan 1, 2025
50.09 M AUD
The Genetic Signatures Equity history
YEAREquityYoY
50.09 MAUD-18.02%
61.10 MAUD+42.38%
42.91 MAUD-21.69%
54.80 MAUD+11.07%
49.34 MAUD+7.43%
45.93 MAUD+334.56%
10.57 MAUD-21.12%
13.40 MAUD-18.72%
16.49 MAUD+252.27%
4.68 MAUD-33.69%
7.06 MAUD+170.38%
2.61 MAUD—
Access this data via the Eulerpool API
Get Free API Key

Genetic Signatures Stock analysis

What does Genetic Signatures do? Genetic Signatures is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Genetic Signatures's Equity

Genetic Signatures's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Genetic Signatures's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Genetic Signatures's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Genetic Signatures's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Genetic Signatures’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Genetic Signatures stock

The Equity of Genetic Signatures is 50.09 M AUD in 2026.

The Equity of Genetic Signatures changed from 61.10 M AUD to 50.09 M AUD, representing a -18.02% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity Genetic Signatures since 2006 – with annual values, charts, and detailed analysis.

The Equity's AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Genetic Signatures historically and in real time.

Access this data via the Eulerpool API
Get Free API Key

Balance Sheet — Genetic Signatures

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Genetic Signatures